Why the study?
Does the SARS-CoV-2 variant BA.2.86 show resistance to clinically relevant monoclonal antibodies and prevailing serum neutralizing antibody responses?
Does the SARS-CoV-2 variant BA.2.86 show resistance to clinically relevant monoclonal antibodies and prevailing serum neutralizing antibody responses?
Absolute Event Rate: 84% vs 130%
The study characterizes the neutralization profile of the highly mutated SARS-CoV-2 BA.2.86 variant against monoclonal antibodies and human sera.
A new SARS-CoV-2 variant, designated BA.2.86, has recently emerged with over 30 spike mutations relative to its parental BA.2, raising questions about its degree of resistance to neutralising antibodies. Using a spike-pseudotyped virus model we characterise neutralisation of BA.2.86 by clinically relevant monoclonal antibodies and by two cohorts of serum sampled from Stockholm, including both a recent cohort, and one sampled prior to the arrival of XBB in Sweden.
No takes yet. Share an insight, caveat, or question.
Sheward et al. (2023) studied SARS-CoV-2 (n=24). SARS-CoV-2 BA.2.86 variant vs. BA.2 and XBB.1.5 variants was evaluated on Neutralizing antibody ID50 titers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: